ENZC
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $0 | — |
| 2025 Q1 | 0.00 | $0 | — |
| 2024 Q4 | -0.00 | $0 | — |
| 2024 Q3 | 0.00 | $0 | — |
| 2024 Q2 | 0.00 | $0 | $115M |
| 2024 Q1 | -0.00 | $0 | -$22,754 |
| 2023 Q3 | -0.00 | $84,951 | $956,428 |
| 2023 Q2 | -0.00 | $39,590 | -$1M |